Uplifting News

11146 readers

9 users here now

Welcome to /c/UpliftingNews, a dedicated space where optimism and positivity converge to bring you the most heartening and inspiring stories from around the world. We strive to curate and share content that lights up your day, invigorates your spirit, and inspires you to spread positivity in your own way. This is a sanctuary for those seeking a break from the incessant negativity often found in today's news cycle. From acts of everyday kindness to large-scale philanthropic efforts, from individual achievements to community triumphs, we bring you news that gives hope, fosters empathy, and strengthens the belief in humanity's capacity for good.

Here in /c/UpliftingNews, we uphold the values of respect, empathy, and inclusivity, fostering a supportive and vibrant community. We encourage you to share your positive news, comment, engage in uplifting conversations, and find solace in the goodness that exists around us. We are more than a news-sharing platform; we are a community built on the power of positivity and the collective desire for a more hopeful world. Remember, your small acts of kindness can be someone else's big ray of hope. Be part of the positivity revolution; share, uplift, inspire!

founded 1 year ago

MODERATORS

WandererLagomorph770

wolfeh

160

Experimental antibiotic kills deadly superbug, opens whole new class of drugs (arstechnica.com)

submitted 9 months ago by alphacyberranger to c/upliftingnews

8 comments fedilink hide all child comments

you are viewing a single comment's thread
view the rest of the comments

[–] [email protected] 2 points 9 months ago

i think the key here is:

zosurabalpin doesn't seem to work on any other Gram-negative bacteria besides A. baumannii. The proteins in the LPS transporter complex are not conserved across different bacteria. Thus, targeting the LPS transporters of other nefarious Gram-negative bacteria will take yet more drug development research. One bright side of this, as Gugger and Hergenrother note in their commentary, is that it may produce species-specific antibiotics, which could protect patients' microbiomes from being obliterated by broad-spectrum drugs, which we now appreciate is bad for human health.

And, of course, with any new antibiotic, there's the inevitability that bacteria will develop resistance. The researchers already found that select mutations in the LPS transporter machinery can knock back the drug's potency. Also, A. baumannii doesn't need LPS to stay alive. That said, simply blocking LPS production would leave A. baumannii more vulnerable, and it's unclear how that trade-off will play out in clinical settings.